ArticleLiver cancer2023

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma.

Heewon Bae et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.